Neumora Therapeutics
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
Company
Deck Type
IPO
Sector
Industry
Deck date
September 2023
Slide
31 of 32
Related slides by other companies
AstraZeneca
Results
November 2024
inflammatory diseases a a | AstraZeneca
BioAtla
Investor Presentation
January 2024
phase cab demographics tumor types | BioAtla
Oculis
Investor Presentation
April 2024
phase a well tolerated by patients to me atone a | Oculis
Ocuphire Pharma
Investor Day
January 2022
safety summary from phase and phase studies way | Ocuphire Pharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights